Skip to content
OccuflowBIO
01contact

Contact

financing

A $3M post-money SAFE to reach IND.

indicative terms
Post-money SAFE
raise
$3M
cap
$12M
discount
20%

Indicative and non-binding. Subject to definitive documents and accredited-investor verification.

indicative use of proceeds
GLP ocular toxicology & tolerability35%
GMP first-in-human supply & CMC25%
Ocular pharmacokinetics & tissue distribution15%
Formulation lock & analytical methods15%
Pre-IND regulatory & bioanalytical10%

Allocations are indicative and subject to change. Accredited investors only. This website is not an offer to sell or a solicitation to buy any security. Any offer would be made only to qualified investors via definitive documentation.

02contacts
primary contact
Gulab S. Zode, PhD
Founder & Chief Executive Officer, OccuFlow Bio, Inc.
Professor of Ophthalmology · Gavin Herbert Eye Institute · UC Irvine
gzode@hs.uci.edu
investor inquiries
investors@occuflowbio.com
Mike Hill · Managing Director, Capital & Growth · Octane
mike@octaneoc.org
03inquiry form

For accredited investors and institutional partners only. No patient inquiries.

OccuflowBIO

A preclinical-stage ophthalmic biotechnology company developing OF-01 to restore the eye's natural drainage architecture in glaucoma.

contact
  • gzode@hs.uci.edu
  • mike@octaneoc.org
  • 505(b)(2) regulatory pathway
investigational product disclaimer

OF-01 is an investigational new drug candidate. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority and has not been demonstrated to be safe or effective for any use. All data described on this website are preclinical. Information provided is for scientific, corporate, and qualified-investor purposes only and is not medical advice.

important disclosures

Preclinical Data: Results described are from in vitro, ex vivo human donor tissue, and animal models, some unpublished. Preclinical findings do not reliably predict results in humans.

Forward-Looking Statements: Statements on development plans, regulatory pathway, timelines, and potential outcomes are forward-looking and subject to substantial uncertainty.

No Offer of Securities: This website is not an offer to sell or a solicitation to buy any security.

No Third-Party Endorsement: Universities and institutions named (including UC Irvine) are identified for background only and do not endorse OccuFlow Bio or OF-01.

© 2026 OccuFlow Bio. All rights reserved.
PRECLINICAL · OF-01 · OPHTHALMOLOGY

Research conducted at UC Irvine (no endorsement implied). OF-01 is an investigational product. Safety and efficacy have not been established.